A Phase I Trial of BKM120 in Combination With Weekly Nabpaclitaxel (Abraxane) in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Recurrent Endometrial or Recurrent Ovarian Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2015
Price : $35 *
At a glance
- Drugs Buparlisib (Primary) ; Paclitaxel (Primary)
- Indications Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 23 Mar 2015 Last checked against ClinicalTrials.gov record.
- 19 Mar 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.